CompanyPrivateBurlington, MA

Cardurion Pharmaceuticals, Inc

SEC EDGAR ClinicalTrials.gov

10-QAug 6Latest SEC filing, period to Jun 30

Form DJul 24$260M sold

August 2026

Cardurion registers Phase 2 CALIBRATE-HF trial of CaMKII inhibitor CRD-4730 in HFrEF

Aug 6Trial updateCardurion Pharmaceuticals, Inc CRD-4730